Halsey Associates Inc. CT Has $443,000 Stake in Becton Dickinson and Co (NYSE:BDX)

Halsey Associates Inc. CT lowered its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 98.1% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,850 shares of the medical instruments supplier’s stock after selling 94,225 shares during the period. Halsey Associates Inc. CT’s holdings in Becton Dickinson and were worth $443,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of BDX. Hudson Bay Capital Management LP grew its position in shares of Becton Dickinson and by 119.9% in the 2nd quarter. Hudson Bay Capital Management LP now owns 166,094 shares of the medical instruments supplier’s stock valued at $39,789,000 after buying an additional 90,564 shares during the last quarter. Parsons Capital Management Inc. RI grew its position in shares of Becton Dickinson and by 3.5% in the 2nd quarter. Parsons Capital Management Inc. RI now owns 7,262 shares of the medical instruments supplier’s stock valued at $1,740,000 after buying an additional 246 shares during the last quarter. American Century Companies Inc. grew its position in shares of Becton Dickinson and by 0.7% in the 2nd quarter. American Century Companies Inc. now owns 1,196,281 shares of the medical instruments supplier’s stock valued at $286,581,000 after buying an additional 7,843 shares during the last quarter. Kiwi Wealth Investments Limited Partnership bought a new stake in shares of Becton Dickinson and in the 2nd quarter valued at about $9,161,000. Finally, Norinchukin Bank The grew its position in shares of Becton Dickinson and by 2.7% in the 1st quarter. Norinchukin Bank The now owns 144,476 shares of the medical instruments supplier’s stock valued at $31,308,000 after buying an additional 3,816 shares during the last quarter. 92.51% of the stock is owned by institutional investors.

A number of research firms have commented on BDX. Morgan Stanley upped their price target on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research report on Thursday, October 4th. Wells Fargo & Co upped their price target on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research report on Thursday, September 6th. They noted that the move was a valuation call. Citigroup upped their price target on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Royal Bank of Canada reiterated a “hold” rating and issued a $248.00 price target on shares of Becton Dickinson and in a research report on Friday, August 3rd. Finally, KeyCorp restated a “buy” rating and set a $264.00 target price on shares of Becton Dickinson and in a research report on Friday, August 3rd. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $253.79.

Shares of Becton Dickinson and stock opened at $250.37 on Tuesday. Becton Dickinson and Co has a one year low of $195.72 and a one year high of $265.87. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. The stock has a market cap of $69.83 billion, a P/E ratio of 26.41, a price-to-earnings-growth ratio of 1.78 and a beta of 1.11.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 EPS for the quarter, beating the consensus estimate of $2.86 by $0.05. The company had revenue of $4.28 billion for the quarter, compared to analyst estimates of $4.25 billion. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The firm’s revenue for the quarter was up 41.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.46 EPS. Equities research analysts expect that Becton Dickinson and Co will post 11.01 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 28th. Shareholders of record on Friday, September 7th were issued a $0.75 dividend. The ex-dividend date was Thursday, September 6th. This represents a $3.00 annualized dividend and a yield of 1.20%. Becton Dickinson and’s payout ratio is currently 31.65%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Read More: How Do You Calculate Return on Equity (ROE)?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply